What is the clinical evidence from this study?

Study design: Case Report. Population: Chronic prothrombotic disorders (VITT-like monoclonal gammopathy of thrombotic significance) (n=5). Intervention: VITT-like antibodies (M proteins). Primary outcome: Identification and characterization of VITT-like antibodies.

What does this research mean for the field?

Chronic anticoagulant-refractory thrombosis and intermittent thrombocytopenia can be caused by VITT-like anti-platelet factor 4 monoclonal antibodies (M proteins) with distinct clonotypes and binding epitopes, defining a novel entity termed VITT-like monoclonal gammopathy of thrombotic significance. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

February 12, 2025New England Journal of Medicine

VITT-like Monoclonal Gammopathy of Thrombotic Significance

View Full Paper

Ask AI

Bookmark

Key result

VITT-like antibodies in chronic prothrombotic disorders manifest as monoclonal M proteins at median ~0.14 g/dL.

Population

5 patients with chronic prothrombotic disorders featuring anticoagulant-refractory thromboses and…

Design

Case_series

Authors

JWJing Jing WangSouth Australia Pathology TWTheodore E. WarkentinHamilton General Hospital LSLinda SchönbornUniversitätsmedizin Greifswald

Discussion

Member takes

Implication

Identifies a novel chronic prothrombotic disorder driven by VITT-like monoclonal gammopathy, highlighting the need for treatments beyond anticoagulation.

Study Design

Type

Case Report (n=5)

Structured PICO

Population

5 patients with chronic prothrombotic disorders featuring anticoagulant-refractory thromboses and intermittent thrombocytopenia associated with VITT-like antibodies.

Outcome

Identification of M protein as the VITT-like antibody and characterization of clonotype profiles and binding epitopessurrogate

Identifies a novel chronic prothrombotic disorder driven by VITT-like monoclonal gammopathy, highlighting the need for treatments beyond anticoagulation.

Cite This Study

Wang et al. (2025) conducted a case report in Chronic prothrombotic disorders (VITT-like monoclonal gammopathy of thrombotic significance) (n=5). VITT-like antibodies (M proteins) was evaluated on Identification and characterization of VITT-like antibodies. In 5 patients with chronic prothrombotic disorders, VITT-like antibodies were identified as M proteins (median level, 0.14 g/dL) with distinct clonotype profiles and binding epitopes on PF4.

synapsesocial.com/papers/6aa2b4eed3d42046dea5895b https://doi.org/10.1056/nejmoa2415930

View Full Paper

Ask AI

Bookmark

Implication

Identifies a novel chronic prothrombotic disorder driven by VITT-like monoclonal gammopathy, highlighting the need for treatments beyond anticoagulation.

VITT-like Monoclonal Gammopathy of Thrombotic Significance

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

VITT-like Monoclonal Gammopathy of Thrombotic Significance

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Also Consider

Also Consider